1-4 of 4
Alexis B. Cortot
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Xiuning Le, Hiroshi Sakai, Enriqueta Felip, Remi Veillon, Marina Chiara Garassino, Jo Raskin, Alexis B. Cortot, Santiago Viteri, Julien Mazieres, Egbert F. Smit, Michael Thomas, Wade T. Iams, Byoung Chul Cho, Hye Ryun Kim, James Chih-Hsin Yang, Yuh-Min Chen, Jyoti D. Patel, Christine M. Bestvina, Keunchil Park, Frank Griesinger, Melissa Johnson, Maya Gottfried, Christian Britschgi, John Heymach, Elif Sikoglu, Karin Berghoff, Karl-Maria Schumacher, Rolf Bruns, Gordon Otto, Paul K. Paik
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1117–1126.
https://doi.org/10.1158/1078-0432.CCR-21-2733
Published: 15 March 2022
View article titled, Tepotinib Efficacy and Safety in Patients with <em>MET</em> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Open the PDF for Tepotinib Efficacy and Safety in Patients with <em>MET</em> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice in another window
Includes: Supplementary data
Journal Articles

First-Line Afatinib plus Cetuximab for EGFR-Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study

Alexis B. Cortot, Anne Madroszyk, Etienne Giroux-Leprieur, Olivier Molinier, Elisabeth Quoix, Henri Bérard, Josiane Otto, Isabelle Rault, Denis Moro-Sibilot, Judith Raimbourg, Elodie Amour, Franck Morin, José Hureaux, Lionel Moreau, Didier Debieuvre, Hugues Morel, Aldo Renault, Eric Pichon, Benjamin Huret, Sandrine Charpentier, Marc G. Denis, Jacques Cadranel
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4168–4176.
https://doi.org/10.1158/1078-0432.CCR-20-4604
Published: 01 August 2021
View article titled, First-Line Afatinib plus Cetuximab for <em>EGFR</em>-Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study
Open the PDF for First-Line Afatinib plus Cetuximab for <em>EGFR</em>-Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial

Julien Mazieres, Fabrice Barlesi, Isabelle Rouquette, Olivier Molinier, Benjamin Besse, Isabelle Monnet, Clarisse Audigier-Valette, Anne-Claire Toffart, Patrick Aldo Renault, Séverine Fraboulet, Sandrine Hiret, Bertrand Mennecier, Didier Debieuvre, Virginie Westeel, Philippe Masson, Anne Madroszyk-Flandin, Eric Pichon, Alexis B. Cortot, Elodie Amour, Franck Morin, Gérard Zalcman, Denis Moro-Sibilot, Pierre-Jean Souquet
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3172–3181.
https://doi.org/10.1158/1078-0432.CCR-19-3056
Published: 01 July 2020
View article titled, Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial
Open the PDF for Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial in another window
Journal Articles

Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer—Letter

Alexis B. Cortot, Denis Moro-Sibilot, Jacques Cadranel
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1827.
https://doi.org/10.1158/1078-0432.CCR-15-2824
Published: 31 March 2016
View article titled, Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer—Letter
Open the PDF for Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer—Letter in another window